What is VIP, and why are people interested in it?
Vasoactive intestinal peptide, or VIP, is a signalling peptide the body produces. It affects blood vessels, smooth muscle and immune activity. Aviptadil is a manufactured form of VIP that has been tested as a medicine. [2]
The research interest is understandable: could giving VIP influence inflammation or protect injured lung tissue? Human studies have tested that question, with different results. The product, route and condition matter when interpreting them.
What have the controlled lung trials found?
Intravenous aviptadil, 2022 report. A placebo-controlled trial in 196 people with critical COVID-19 respiratory failure did not find a statistically significant improvement in its primary outcome, being alive and free from respiratory failure at day 60. A secondary analysis found higher odds of survival. That signal was worth following, but it did not turn the missed primary outcome into a positive result. [1]
The larger TESICO trial, 2023 report. This trial randomized 471 people to intravenous aviptadil or placebo; 461 received at least part of an infusion and were included in the main analysis. It found no significant improvement in recovery or mortality through day 90. The aviptadil comparison was stopped for futility, meaning the accumulating data were unlikely to show the intended benefit if it continued. This result needs to be read alongside the earlier survival signal. [2]
Inhaled aviptadil, 2025 report. A smaller randomized study of 80 hospitalized people with COVID-19 pneumonia found a shorter average time to discharge with inhaled aviptadil plus standard care: 7.8 days compared with 10 days with placebo plus standard care. Some breathlessness and imaging measures also improved. The study was small, later follow-up was incomplete, and oxygen measurements were affected by some patients remaining on supplemental oxygen. It supports further study of this inhaled preparation, rather than proving that every VIP treatment is effective. [3]
An earlier inhaled arm also had a negative finding. In March 2022, I-SPY COVID's sponsor reported that nebulized aviptadil did not demonstrate clinical benefit in a controlled comparison of 118 severely or critically ill patients. The arm stopped for prespecified futility. This is a sponsor report from an open-label adaptive trial, with less published detail than a full trial paper. [10]
The inhaled and intravenous findings should not be treated as though they tested the same treatment in the same patients. They also do not establish a benefit for general wellness, chronic fatigue or a nasal spray.
What about sarcoidosis and personal symptom reports?
A 2010 study gave nebulized VIP to 20 people with active sarcoidosis for four weeks. Researchers reported reduced production of the inflammatory messenger TNF-alpha by cells collected from the lungs, and increased regulatory T cells. This was an open-label study without a placebo group. It showed an immune effect, but could not establish how much patients would benefit clinically or how durable any benefit would be. [4]
There is also published human nasal-spray research. A 2013 open-label report followed 20 people described as having chronic inflammatory response syndrome after exposure to water-damaged buildings. It reported improvements in symptoms and laboratory measures during prolonged VIP use after earlier treatment steps. It had no randomized placebo comparison, so it cannot isolate the effect of VIP from other care, changes over time or expectation. [5]
FDA's 2016 review found this report inadequate to establish benefit for the proposed CIRS use. That is different from saying no human nasal-spray report exists. The report provides observations to investigate, with important limits on what it can establish. [6]
For an individual experience, useful details include what changed, how it was measured, how long it lasted and what else was being used. We should listen to those accounts without treating them as a prediction for the next person.
What remains uncertain about safety?
A substance made naturally by the body can still cause problems when given as a treatment. In TESICO, infusion reactions were more frequent with aviptadil. These included low blood pressure, diarrhoea, flushing and a faster heart rate. Some infusions had to be paused, reduced or stopped. These rates came from critically ill patients receiving intravenous treatment; they cannot be transferred directly to another route or population. [2]
Short-term tolerability in a small study does not settle uncommon harms or the safety of prolonged use. FDA's 2016 VIP compounding review also raised concerns about peptide quality, degradation and possible immune reactions, and found the evidence inadequate for the proposed nasal-spray use. [6]
Does VIP have an approved medical use?
Approval depends on the product and country. For example, Norway authorises Invicorp, a combination of aviptadil and phentolamine, for erectile dysfunction in adult men. That is a specific combination injection with its own indication. It does not establish approval or effectiveness for a VIP nasal spray, treatment of lung inflammation or general wellness. [7]
In the United States, FDA's May 2026 list places VIP in Category 1, substances under evaluation for the 503A bulks list. FDA describes conditional enforcement discretion for this category while its review continues. That is a compounding pathway subject to requirements, not approval of a VIP drug or proof of benefit. [8] [9]
Ask the prescriber to identify the exact product and explain its status in the jurisdiction where it would be supplied. Drug approval, access to a compounded preparation and participation in a clinical trial are different questions.
What should someone ask before considering VIP?
- Which condition are we trying to address, and what evidence supports this particular use?
- Is this aviptadil, a different VIP analogue or a combination product?
- Does the proposed route match the study being cited?
- How do the positive and negative trials affect the expectations for this situation?
- What monitoring is needed, and what symptoms or measurements would prompt a change or a stop?
VIP has a real human research record. Reading it fairly means keeping the encouraging findings, the negative trials and the limitations together. For help interpreting a trial, see How to Read a Regenerative Medicine Study.
Questions people ask
Did the COVID-19 trials prove that aviptadil works?
The results differ. The 2022 intravenous trial missed its primary outcome but reported a secondary survival signal. The larger TESICO trial found no significant clinical benefit. A smaller 2025 inhaled study reported faster discharge. An earlier inhaled I-SPY arm stopped for futility, according to its sponsor. These were different routes and patient groups. [1] [2] [3] [10]
Has VIP nasal spray been studied in people?
Yes. A small open-label CIRS report described improvements, but it lacked a randomized placebo comparison. It does not establish that nasal VIP caused those improvements or that the results apply to other conditions. [5]
Does approval of Invicorp cover other VIP products?
No. Invicorp is a specific aviptadil/phentolamine combination for erectile dysfunction. Its authorisation does not transfer to other preparations, routes or uses. [7]
Sources and further reading
Sources checked November 5, 2026. Original full texts were reviewed for the 2022 and 2025 COVID-19 trials and the CIRS report. TESICO and sarcoidosis findings were checked against their published abstracts and accessible full-text sections. The I-SPY finding is identified separately as a sponsor report. The historical FDA review, current compounding list and Norwegian product information were checked separately from trial evidence.
This article is educational and is not personal medical advice. A qualified treating clinician should assess your condition and discuss suitable options, expected benefits and risks. Any treatment decision should be made with a qualified physician. Individual results vary.